Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.

Denise L CecilKyong Hwa ParkBenjamin CurtisLauren CorulliMary Nora Disis

Published in: Journal for immunotherapy of cancer (2021)

These data suggest the clinical activity of type I T cells extends beyond direct tumor killing and immune therapies designed to increase type I T cells and could be integrated into standard chemotherapy regimens to enhance therapeutic efficacy.

Keyphrases

locally advanced
signaling pathway
electronic health record
big data
squamous cell carcinoma
rectal cancer
chemotherapy induced
radiation therapy
combination therapy
induced apoptosis
data analysis